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INTRODUCTION 
The liver functions primarily as a metabolic organ and 
is in constant exposure to dietary and microbial antigens 
[1]. Liver disease includes many diverse conditions, 
diseases and infections that affect the morphology and 
function of the liver, alterations in the liver function test 
(LFT) easily observable manifestations of liver disease 
[2]. 
Cirrhosis is the final stage of chronic liver disease. It 
results in distortion of the hepatic architecture by fibro-
sis, and the formation of regenerative nodules [3]. It is 
the result of progressive liver fibrosis caused by chronic 
liver diseases, including viral hepatitis, alcoholic liver 
disease, non-alcoholic steatohepatitis (NASH), autoim-
mune liver disease, and genetic disorders, amongst oth-
ers [4]. 
Alcohol is also a frequent co-factor in patients with oth-
er type of liver disease such as hepatitis C virus (HCV) 
infection where it accelerates hepatic fibrosis [5]. Ow-
ing to various susceptibility factors, individuals with 
long-term heavy alcohol use remain at risk for advanced 
liver disease with alcoholic steatohepatitis (ASH), cir-
rhosis, and hepatocellular carcinoma (HCC) [6]. Alco-
hol abuse or alcohol dependence is not synonymous 
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with clinically important ALD, as only about 10–20% 
of chronic heavy drinkers develop severe forms such as 
AH or cirrhosis [7].   
Hepatitis means “inflammation of the liver”. Five types 
of viruses can cause viral hepatitis. Of these, the most 
common cause of infection is one of four viruses: hepa-
titis A, B, C or E. Hepatitis D, also referred to as hepati-
tis D virus, or hepatitis delta virus (HDV) is considered 
to be a sub viral satellite because it can propagate only 
in the presence of the hepatitis B virus (HBV). All or 
any of these viruses can cause an acute disease, with 
symptoms lasting several weeks, including yellowing of 
the skin and eyes (jaundice), dark urine, extreme fa-
tigue, nausea, vomiting and abdominal pain. It can take 
several months to a year to feel fit again. Easily con-
tracted in many ways, from drinking water to casual 
contact or sexual intercourse, this debilitating disease 
poses a risk to everyone [8]. 
Obstructive jaundice results from biliary obstruction, 
which is blockage of any duct that carries bile from liver 
to gallbladder and then to small intestine [9]. The most 
common causes of obstructive jaundice are cholelithia-
sis, structures of the biliary tract, cholangio-carcinoma, 
carcinoma of pancreas, pancreatitis, parasites and pri-
mary sclerosing cholangitis [10]. The prevalence of 
gallbladder and bile duct stones rises with age [11]. Up 
to 90% of patients with pancreatic head carcinoma ex-
hibit the signs and symptoms of obstructive jaundice at 
the time of presentation [12].  
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MATERIAL AND METHODOLOGY    
Study design: An observational case control study  
Ethics approval: The study protocol was approved by 
the institutional ethics committee. A written informed 
consent was obtained from each subject. 
Research place: The study was conducted in the De-
partment of Biochemistry association with Department 
of General Medicine, at SVS Medical College and Hos-
pital, Mahabubnagar District, Telangana State, India. 
Sample size: One hundred were included in the study  
Inclusion criteria: The study included (n=80) various 
liver disease patients admitted to General Medicine De-
partment. Patient age group of 35 to 55 years. In these 
(n=20) were diagnosed as cirrhosis, (n=20) were alco-
holic liver disease, (n=20) were viral hepatitis, (n=20) 
obstructive jaundice. Controls (n=20) subjects were 
hospital staff having normal health within the age group 
of 30-55 years. 
Exclusion criteria: Patients suffering with other chron-
ic liver diseases, cardiac problems, on tuberculosis treat-
ment and higher antibiotics on long term 
The data on personal history, regarding the onset of the 
disease, alcohol consumption and treatment history for 
liver disease were collected through standard question-
naire. 
The present study was taken up to estimate serum levels 
in Bilirubin, AST, ALT, ALP and Gamma Glutamyl 
Transferase (GGT) parameters among the subjects suf-
fering with various liver diseases. 
Methodology:  
Sample collection: Blood samples were collected from 
both cases and controls. 5 ml of random blood with-
drawn from a cubital vein into blood tubes. The serum 
was then separated from the cells by centrifugation at 
3000 rpm for 10 min. 
In the serum estimated Bilirubin by Jendrassik Groff`s 
method, AST by UV kinetic method, ALT by UV kinet-
ic method, ALP by PNP AMP kinetic method, and GGT 
by Colorimetric method, by using Siemens-ADVIA 
Chemistry XPT system Auto analyzer.  
And reference ranges are Total Bilirubin: 0.2-1.0 mg/dl, 
Aspartate Transaminase: 4-45 IU/L, Alanine Transami-
nase: 3-40 IU/L, Alkaline Phosphatase: 25-80 IU/L, 
Gamma Glutamyl Transferase:10-45 U/L 
Statistical analysis: The descriptive results were ex-
pressed as Mean and Standard deviation. Significance of 
the difference between the patient and control groups 
observed was assessed by using the student t-test.  
 
RESULTS  
The results of this study showed that the increase in 
serum levels of Bilirubin, AST, ALT, ALP and GGT in 
various types of liver diseases i.e Cirrhosis of liver, Al-
coholic Liver Disease, Viral hepatitis, Obstructive jaun-
dice when compared with control serum levels. (Table 
1) 
DISCUSSION 
The present study involves estimation of parameters 
relating to inflammatory process, defense mechanism of 
the individual and also the products for damage caused 
to the cells in liver disease. The estimated parameters of 
or enzymes are Bilirubin, AST, ALT, ALP and GGT 
related to hepatocellular damage. 
The present study includes 80 subjects who are diagno-
sis to be having liver disease due to some reasons or 
others. The above estimated parameters were compared 
with the same parameters obtained from control group 
comprised of 20 individuals. 
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0.6±0.15 4.015±2.03 6.23±2.4 5.12±2.26 11.2±3.34 <0.001 
AST (IU/L) 21.05±4.5 95.0±9.7 239.2±15.4 290.0±17.1 91.9±9.5 <0.001 
ALT (IU/L) 24 ± 4.8 98.5±9.9 152.0±12.3 499.3±22.3 96.35±9.81 <0.001 
ALP (IU/L) 118.2±10.8 151.15±12.3 222.15±17.5 183.85±13.6 678.45±26 <0.001 
GGT (U/L) 23 ± 4.7 -- 480.0±21.9 -- -- <0.001 
p-Value ≤ 0.001 was considered statistically highly significant.  
The serum Bilirubin levels are increased when compared with control. The p-Value (< 0.001) is comparatively highly 
significant when compared with controls.   
The serum AST, ALT, ALP levels are increased and p-Value (< 0.001) is comparatively highly significant when com-
pared with controls.  
The p-value of CGT (< 0.001) is comparatively highly significant when compared with controls.  
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The various enzymatic parameters included in LFT’s 
are Serum Bilirubin, AST, ALT, ALP and GGT. The 
present study it is observed that obstructive Jaundice 
shows a highest rise in Serum Bilirubin levels, followed 
by Alcoholic Liver Disease, Viral Hepatitis, Cirrhosis of 
liver. Respectively. Viral Hepatitis shows a highest rise 
in AST levels, followed by Alcoholic Liver Disease, 
Cirrhosis of liver and Obstructive Jaundice, respective-
ly. The obstructive jaundice shows a highest rise in ALP 
levels followed by Alcoholic Liver Disease.  
The present study has shown that significant increased 
serum levels of Bilirubin, AST, ALT, ALP and GGT in 
obstructive Jaundice, viral Hepatitis, cirrhosis of Liver, 
alcoholic Liver Disease in cases when compared with 
controls. 
In earlier studies shown that ALT exceeds AST in toxic 
hepatitis, viral hepatitis, chronic active hepatitis and 
cholestatic hepatitis by Rosalki SB et.al [13]  
Previous studies shown that increased bilirubin, ALP 
levels in obstructive jaundice [14]. Earlier studies 
shown that levels of Aspartate Aminotransferase (AST) 
and Alanine Aminotransferase (ALT) are moderately 
elevated in cirrhosis; however, normal Aminotransfer-
ase levels do not exclude cirrhosis. Alkaline phospha-
tase is usually mildly elevated in cirrhosis [15] 
In earlier studies shown the increase of GGT in alcohol-
ic liver disease done by Wu. A. et al [16], Selinger M. J. 
et al [17] 
The results of the present study also shown coincides 
with earlier studies in obstructive jaundice, viral hepati-
tis, cirrhosis of liver, alcoholic liver disease respectively 
[13-17] 
CONCLUSION 
Most of the liver disease are asymptomatic. A simple 
and easy biochemistry laboratory investigation i.e. Liver 
Function Test (LFT) can early diagnose a disease in a 
single visit of a patient and conformed to ultrasonogra-
phy.  
Suggestion: Thus, early diagnosis, treatment can halt 
the progression of liver diseases, modifiable risk factors 
like alcohol can be withdrawn by life style modifica-
tions.  
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